公开(公告)号：US20240352109A1

公开(公告)日：2024-10-24

申请号：US18688264

申请日：2022-08-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Akihiko Koyama ,  Chad Swanson ,  Michio KANEKIYO ,  Michael IRIZARRY ,  Lynn Kramer ,  June KAPLOW ,  David VERBEL ,  Shobha DHADDA ,  Pallavi SACHDEV ,  Larisa REYDERMAN ,  Ishani Landry ,  Seiichi HAYATO ,  Robert Gordon

IPC: C07K16/18 ,  A61K9/00 ,  A61K39/00 ,  A61K47/18 ,  A61K47/26 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K47/183 ,  A61K47/26 ,  A61P25/28 ,  A61K2039/505 ,  A61K2039/545

Abstract: Disclosed herein are methods of treating Alzheimer's disease, methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of reducing brain amyloid level in a subject, methods of converting a subject from amyloid positive to amyloid negative, methods of preventing Alzheimer's disease, the methods comprising subcutaneously administering an anti-Aβ protofibril antibody.

公开(公告)号：US20220305012A1

公开(公告)日：2022-09-29

申请号：US17597074

申请日：2020-06-25

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Margaret MOLINE ,  Lynn KRAMER ,  Shobha DHADDA

IPC: A61K31/506 ,  A61P25/20

Abstract: Methods of improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in subjects comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof are disclosed herein. Also disclosed herein is lemborexant or a pharmaceutically acceptable salt thereof for use in improving subjective sleep efficiency, reducing subjective sleep onset latency, and/or reducing subjective wake after sleep onset in a subject comprising administering to the subject 5 mg or 10 mg of lemborexant or an equivalent dose of a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250163135A1

公开(公告)日：2025-05-22

申请号：US18577174

申请日：2022-07-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Chad SWANSON ,  Akihiko KOYAMA ,  Michio KANEKIYO ,  Michael IRIZARRY ,  Lynn KRAMER ,  June KAPLOW ,  David VERBEL ,  Shobha DHADDA ,  Pallavi SACHDEV ,  Larisa REYDERMAN ,  Seiichi HAYATO, ,  Ishani LANDRY ,  Robert GORDON

IPC: C07K16/18 ,  A61K39/00 ,  G01N33/68

Abstract: Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

公开(公告)号：US20250051427A1

公开(公告)日：2025-02-13

申请号：US18720518

申请日：2022-11-08

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  WASHINGTON UNIVERSITY

Inventor： Larisa REYDERMAN ,  Jin ZHOU ,  Lynn KRAMER ,  Michael IRIZARRY ,  Pallavi SACHDEV ,  Shobha DHADDA ,  David LI ,  Kristin WILDSMITH ,  Pau ACEVES BALDO ,  Sumit RAWAL ,  Akihiko KOYAMA ,  Chad SWANSON ,  Michio KANEKIYO ,  June KAPLOW ,  David VERBEL ,  Ishani LANDRY ,  Seiichi HAYATO ,  Robert GORDON ,  Randall BATEMAN ,  Eric MCDADE

IPC: C07K16/18 ,  A61K39/00

Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-Aβ protofibril antibody and anti-tau antibody.

公开(公告)号：US20250022603A1

公开(公告)日：2025-01-16

申请号：US18523799

申请日：2023-11-29

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Viswanath DEVANARAYAN ,  Shobha DHADDA ,  Michael IRIZARRY

IPC: G16H50/30 ,  G06N20/00 ,  G16B20/00 ,  G16B25/10

Abstract: A platform is disclosed for the training and deployment of statistical or machine-learning models for predicting the progression of cognitive impairment or brain amyloid status. The statistical or machine-learning models can be trained to predict the progression of cognitive impairment or brain amyloid status using baseline image data, biomarker data, genomic data, demographic data, cognitive data, or the like. The platform can be configured to obtain training data, train the statistical or machine-learning models, and support using the trained statistical or machine-learning models to respond to prediction requests.

公开(公告)号：US20210324056A1

公开(公告)日：2021-10-21

申请号：US17250448

申请日：2019-07-23

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Johan LUTHMAN ,  Chad J. SWANSON ,  Yong ZHANG ,  Shobha DHADDA ,  Jinping WANG ,  Lynn KRAMER

IPC: C07K16/18 ,  A61K31/542 ,  A61P25/28

Abstract: Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.